Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 153-163 , March 2010

131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors

  • Frank Grünwald, PhD, MD

      Affiliations

    • Department of Nuclear Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany
    • Corresponding Author InformationAddress reprint requests to Frank Grünwald, PhD, MD, Department of Nuclear Medicine, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany
    • ,
  • Samer Ezziddin, MD

      Affiliations

    • Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

References 

  1. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–1053
  2. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992;52:538–543
  3. Brodeur M, Castleberry RP. Neuroblastoma. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatrics. Philadelphia, PA: Lippincot-Raven; 1997;p. 761–797
  4. Matthay KK. Neuroblastoma. In:  Pochedly C editors. Neoplastic Diseases in Childhood. Chur, Switzerland: Harwood; 1994;p. 735–778
  5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–1173
  6. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23:6459–6465
  7. Marris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369:2106–2120
  8. Brodeur M, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477
  9. Wieland DM, Wu JL, Brown LE, et al. Radiolabeled adrenergi neuron-blocking agents: Adrenomedullary imaging with [131-I]iodobenzylguanidine. J Nucl Med. 1980;21:349–353
  10. McEwan AJ, Shapiro B, Sisson JC, et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med. 1985;15:132–153
  11. Hattner RS, Huberty JP, Engelstad BL, et al. Localization of m-iodo (131-I) benzylguanidine in neuroblastoma. AJR Am J Roentgenol. 1984;143:373–374
  12. Leung A, Shapiro B, Hattner R, et al. Specificity of radioiodinated MIBG for neutral crest tumors in childhood. J Nucl Med. 1997;38:1352–1357
  13. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–372
  14. Attiyeh EF, London WB, Mosse YP, et al. Childrens Oncology Group: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–2253
  15. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–1961
  16. Zaplatnikov K, Menzel C, Döbert N, et al. Case report: Drug interference with MIBG uptake in patient with metastatic paraganglioma. Br J Radiol. 2004;77:525–527
  17. Wafelman AR, Nortier YL, Rosing H, et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun. 1995;16:767–772
  18. Ehninger G, Klingebiel T, Kumbier I, et al. Stability and pharmacokinetics of m-131I-iodobenzylguanidine in patients. Cancer Res. 1987;47:6147–6149
  19. Klingebiel T, Treuner J, Ehninger G, et al. 131 I-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma (Clinical, pharmacological, and dosimetric aspects). Cancer Chemother Pharmacol. 1989;25:143–148
  20. Dubois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35(suppl 1):S35–S48
  21. Sudbrock F, Eschner W, Schmidt M, et al. Dosimetry for therapeutic treatment of neuroblastoma by 131I-MIBG. Nuklearmedizin. 2006;6:254–261
  22. Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with 131I meta-iodobenzylguanidine. Cancer. 1991;67:922–928
  23. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer. 1999;81:1378–1384
  24. Hoefnagel CA, Voute PA, de Kraker J, et al. 131I-metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med. 1991;35:202–206
  25. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy (A pilot trial). Eur J Cancer. 1998;34:1398–1402
  26. Klingebiel T, Berthold F, Treuner J, et al. (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial. Med Pediatr Oncol. 1991;19:84–88
  27. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II trial of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992;10:1889–1896
  28. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229–236
  29. Sisson JC, Shapiro B, Hutchinson RJ, et al. Survival of patients with neuroblastomas treated with 125I MIBG. Am J Clin Oncol. 1996;19:144–148
  30. Troncone L, Rufini V, Montemaggi P, et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med. 1990;16:325–335
  31. Schmidt M, Simon T, Hero B, et al. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma?. Nuklearmedizin. 2006;45:145–151
  32. Menzel C, Graichen S, Berner U, et al. Monitoring the efficacy of iodine-131 MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca. 2003;30:37–40
  33. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403–418
  34. De Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008;44:551–556
  35. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer. 2001;84:460–464
  36. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 2001;27:571–574
  37. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142–2149
  38. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20:195–199
  39. Matthay K, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009;27:1020–1025
  40. Koral KF, Huberty JP, Frame B, et al. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2008;35:2105–2112
  41. Voute PA, van der Kleij AJ, De Kraker J, et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer. 1995;31A:596–600
  42. Diehl M, Fußhoeller G, Menzel C, et al. Hyperbaric oxygen to intensify 131-I-MIBG therapy in refractory neuroblastoma stage 4. Nuklearmedizin. 2004;6:N77–N80
  43. Mastrangelo S, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neuro Oncol. 1997;31:153–158
  44. Mastrangelo R, Tornesello A, Riccardi R, et al. A new approach in the treatment of stage IV neuroblastoma using a combination of 131-I-metaiodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer. 1995;31A:606–611
  45. Sudbrock F, Boldt F, Kobe C, et al. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Nuklearmedizin. 2009;48:17–25
  46. Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513–521
  47. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136:1218–1226
  48. Sywak MS, Pasieka JL, McEwan AJB, et al. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg. 2004;28:1157–1162
  49. Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829–1838
  50. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-MIBG]. Clin Endocrinol (Oxf). 2001;55:47–60
  51. Bomanji JB, Wong W, Gaze MN, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003;15:193–198
  52. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid (Results in 98 patients). Cancer. 2004;101:1987–1993
  53. Safford SD, Coleman RE, Gockerman JP, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956–962discussion 962-963
  54. Nwosu AC, Jones L, Vora J, et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer. 2008;98:1053–1058
  55. Gedik G, Hoefnagel C, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725–733
  56. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162–4168
  57. Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther. 2009;123:117–141
  58. Forrer F, Riedweg I, Maecke HR, et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334–340
  59. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569–585
  60. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648–658
  61. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours. Eur J Nucl Med. 1994;21:561–581
  62. Gao Z, Biersack H-J, Ezziddin S, et al. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol. 2004;130:649–656
  63. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S47–S50
  64. Castellani MR, Seregni E, Maccauro M, et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: Is there still a role?. Q J Nucl Med Mol Imaging. 2008;52:430–440
  65. Buscombe JR, Cwikla JB, Caplin ME, et al. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005;26:969–976
  66. Ezziddin S, Logvinski T, Ahmadzadehfar H, et al. Update zur I-131-MIBG-Therapie beim fortgeschrittenen Karzinoid: Langzeitüberleben und Toxizität bei Anwendung von 11.1 GBq pro Zyklus. Nuklearmedizin. 2008;1–2
  67. Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829–1838
  68. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47:223–233
  69. Forrer F, Waldherr C, Maecke HR, et al. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703–707
  70. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130
  71. Madsen MT, Bushnell DL, Juweid ME, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med. 2006;47:660–667
  72. Brogsitter C, Pinkert J, Bredow J, et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med. 2005;46:2112–2116
  73. Brogsitter C, Pinkert J, Bredow J, et al. Verbesserte intratumorale Retention in neuroendokrinen Tumoren nach intraarterieller Applikation von 131I-MIBG. Nuklearmediziner. 2008;31:132–136
  74. Sisson JC, Shapiro B, Shulkin BL, et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:364–370
  75. Zuetenhorst JM, Valdes Olmos RA, Muller M, et al. Interferon and meta-iodobenzylguanidine combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer. 2004;11:553–561
  76. Taal BG, Hoefnagel C, Boot H, et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol. 2000;11:1437–1443
  77. Zuetenhorst H, Taal BG, Boot H, et al. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidine (MIBG): Pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999;11:1157–1164
  78. Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot. 1993;44:621–628
  79. Mairs RJ, Boyd M. Optimizing MIBGtherapy of neuroendocrine tumors: Preclinical evidence of dose maximization and synergy. Nucl Med Biol. 2008;35(suppl 1):S9–S20
  80. Owens J, Bolster AA, Prosser JE, et al. No-carrier-added 123I-MIBG: An initial clinical study in patients with phaeochromocytoma. Nucl Med Commun. 2000;21:437–440

PII: S0001-2998(09)00113-5

doi: 10.1053/j.semnuclmed.2009.11.004

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 153-163 , March 2010

Article Tools

* Image Usage & Resolution